Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

ClinicalTrials.gov ID: NCT01366131

Public ClinicalTrials.gov record NCT01366131. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin , Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of MEGF0444A combined with paclitaxel + carboplatin + bevacizumab therapy in patients with histologically or cytologically documented inoperable, locally advanced, metastatic (Stage IV), or recurrent non-squamous NSCLC.

Study identification

NCT ID: NCT01366131
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 104 participants

Conditions and interventions

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2011 (Type not available)
Primary completion: Feb 2013 (Actual)
Completion: Not listed
Last update posted: Nov 2, 2016

Started 2011

United States locations

U.S. sites: 20
U.S. states: 16
U.S. cities: 20

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35205	—
Not listed	Hot Springs	Arkansas	71913	—
Not listed	Santa Monica	California	90404	—
Not listed	Orlando	Florida	32904	—
Not listed	Port Saint Lucie	Florida	34952	—
Not listed	St. Petersburg	Florida	33719	—
Not listed	Tampa	Florida	33603	—
Not listed	Marietta	Georgia	30060	—
Not listed	Indianapolis	Indiana	46260	—
Not listed	Wichita	Kansas	67214-3728	—
Not listed	Burnsville	Minnesota	55337	—
Not listed	Las Vegas	Nevada	89148	—
Not listed	Albany	New York	12208	—
Not listed	Columbus	Ohio	43219	—
Not listed	Portland	Oregon	97239	—
Not listed	Hershey	Pennsylvania	17033	—
Not listed	Nashville	Tennessee	37203	—
Not listed	Austin	Texas	78731	—
Not listed	Fort Worth	Texas	76104	—
Not listed	Vancouver	Washington	98684	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01366131, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 2, 2016 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01366131 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →